慢性肺曲霉病:TY - T1的公关evalence, favouring pulmonary diseases and prognosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.03345-2020 SP - 2003345 AU - Maitre, Thomas AU - Cottenet, Jonathan AU - Godet, Cendrine AU - Roussot, Adrien AU - Abdoul Carime, Nafiz AU - Ok, Vichita AU - Parrot, Antoine AU - Bonniaud, Philippe AU - Quantin, Catherine AU - Cadranel, Jacques Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/01/14/13993003.03345-2020.abstract N2 - Chronic pulmonary aspergillosis (CPA) is an emerging disease in patients with common chronic pulmonary diseases (CPD). While its prevalence is linked to tuberculosis (TB) in endemic countries, epidemiologic and prognostic data are lacking in low TB incidence countries. The aim of this study was to describe these features in CPA patients hospitalised in France between 2009 and 2018.We estimated the prevalence and mortality of hospitalised CPA patients using the French nationwide administrative hospital database. We also assessed the association with CPDs, thoracic interventions, and malnutrition.From 2009 to 2018, 17 290 patients were hospitalised in France for CPA, with an increasing prevalence during this period. Most patients were male (63.5%) with a median age of 65 years at CPA diagnosis, living in farming regions and large cities. The proportion of underlying chronic obstructive pulmonary disease (COPD) and emphysema during the previous 5 years was 44% and 22%, respectively, whereas it was only 3% for both TB and non-TB mycobacterial (NTM) infections. The mortality rates during the first hospitalisation, at 1 year, and at 5 years were 17%, 32%, and 45%, respectively. In multivariate analysis, mortality rates were increased in patients aged over 65 years, males and patients with malnutrition, diabetes, or lung cancer history. The risk of mortality in patients with COPD or emphysema was higher compared to those with previous mycobacterial lung infection.In France CPA is an emerging infection commonly associated with non-mycobacterial CPD. This shift in the distribution profile of underlying CPD will likely worsen CPA mortality.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Maitre has nothing to disclose.Conflict of interest: Dr. Cottenet has nothing to disclose.Conflict of interest: Cendrine Godet: received consultancy or speaker fees, travel support from Pfizer, Astellas, Gilead, MSD, SOS Oxygene, Elivie, Pulmatrix and ISIS Medical.Conflict of interest: Dr. Roussot has nothing to disclose.Conflict of interest: Dr. Abdoul Carime has nothing to disclose.Conflict of interest: Dr. Ok has nothing to disclose.Conflict of interest: Dr. Parrot has nothing to disclose.Conflict of interest: Dr. Bonniaud has nothing to disclose.Conflict of interest: Dr. Quantin has nothing to disclose.Conflict of interest: Dr. Cadranel has nothing to disclose. ER -